Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hMPV_Y low dose vaccine is an investigational human metapneumovirus (hMPV) vaccine candidate developed by GSK. It was evaluated as part of a Phase 1/2 clinical trial (NCT04141540) designed to assess the safety, reactogenicity, and immunogenicity of various hMPV and RSV/hMPV combination vaccine formulations in younger adults (18-49 years) and older adults (60-80 years). The 'Y' designation refers to a specific investigational formulation of the hMPV vaccine, administered at a low dose via intramuscular injection. The vaccine aims to elicit a protective immune response against hMPV, a significant cause of viral respiratory tract infections, particularly in infants, the elderly, and immunocompromised individuals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hMPV_Y low dose vaccine.